News
Futura Medical PLC - Phase III efficacy study of MED2002
RNS Number: 1570 M Futura Medical PLC 26 April 2018. The trial will be conducted throughout Eastern Europe with a three-month study period for each patient.. Futura is confident that the positive PK data published this month supports the decision to conduct Phase III studies at higher doses than previously studied, and 0.6% GTN is the maximum dose that would...
RNS Number: 1570 M Futura Medical PLC 26 April 2018. The trial will be conducted throughout Eastern Europe with a three-month study period for each patient.. Futura is confident that the positive PK data published this month supports the decision to conduct Phase III studies at higher doses than previously studied, and 0.6% GTN is the maximum dose that would...